Spinal cord injury (SCI) is a serious neurological condition that can disrupt communication between the brain and body. Depending on the severity and location of the injury, patients may experience changes in movement, sensation, autonomic function, bladder or bowel control, and overall independence. Because damage to the spinal cord can involve both the initial physical injury and ongoing secondary effects such as inflammation, oxidative stress, and tissue changes, SCI remains one of the most challenging areas of neurological care.
Current treatment approaches often focus on stabilizing the spine, reducing further damage, and supporting rehabilitation. While these steps are important, researchers continue to explore new regenerative medicine strategies that may help support nerve repair, reduce inflammation, and improve the environment surrounding damaged spinal cord tissue.
In this review published in International Journal of Molecular Sciences, researchers examined clinical studies involving mesenchymal stem/stromal cell (MSC)-based therapies for spinal cord injury. The review focused on safety, feasibility, treatment methods, cell sources, routes of administration, and clinical outcomes reported across published studies.
Why Researchers Are Studying MSCs for Spinal Cord Injury
Mesenchymal stem cells have become one of the most widely studied cell types in regenerative medicine because of their ability to release helpful biological signals, interact with immune cells, and support tissue repair processes. In spinal cord injury, researchers are especially interested in MSCs because they may help influence several repair-related pathways at once.
Rather than simply replacing damaged nerve cells directly, MSCs appear to work largely through paracrine signaling. This means they release bioactive factors that communicate with nearby cells and help influence the surrounding tissue environment. These signals may support inflammation control, cellular survival, blood vessel formation, extracellular matrix remodeling, and neuroprotective activity.
The review also discusses MSC-derived exosomes, which are small extracellular vesicles released by MSCs. These vesicles can carry proteins, RNA, growth factors, and other molecules involved in cell communication. In regenerative medicine research, MSC-derived exosomes are being studied for their potential to support repair, reduce inflammation, and promote a more favorable environment for healing.
Study Overview
The authors reviewed 26 clinical studies involving MSC-based therapy for patients with spinal cord injury. These studies included patients with different degrees of neurological impairment and varied in design, treatment timing, MSC source, dose, delivery route, and follow-up period.
The review analyzed several important features of the clinical studies, including:
- The type and source of MSCs used
- The dose of cells administered
- The route of transplantation
- Patient inclusion criteria
- Safety and tolerability
- Neurological and functional outcomes
- Methods used to evaluate treatment response
The studies included different methods of MSC administration, including intrathecal delivery, intravenous infusion, and intramedullary injection. Intrathecal delivery, which introduces cells into the cerebrospinal fluid, was one of the most commonly used approaches because it allows the therapy to reach the area surrounding the spinal cord while remaining less invasive than direct injection into the injury site.
Key Findings From the Review
One of the major findings from the review was that MSC transplantation was reported as safe and feasible across the clinical studies summarized by the authors. This is an important point because safety is a foundational part of evaluating any regenerative medicine approach.
The authors also reported varying degrees of patient improvement across the reviewed studies. Some clinical outcomes included improvements in sensory function, motor function, neuromuscular conduction, bladder or pelvic organ function, MRI-based observations, and increased independence in daily activities.
The review noted that results varied between studies, which is expected given the differences in injury severity, treatment timing, cell source, administration route, and study design. However, the overall findings suggest that MSC-based therapy continues to be an important area of clinical investigation for spinal cord injury.
How MSCs May Support Neurological Recovery
Spinal cord injury involves more than the original trauma. After the initial injury, secondary processes such as inflammation, oxidative stress, cell death, scarring, and changes in the tissue microenvironment can continue to affect recovery. This is one reason MSCs are being studied so closely: they may influence several of these processes at the same time.
According to the review, MSCs may support spinal cord repair through several mechanisms, including:
- Releasing growth factors and cytokines
- Modulating inflammatory immune responses
- Supporting blood vessel formation
- Reducing oxidative stress
- Promoting tissue remodeling
- Helping protect existing nerve cells
- Influencing the activity of surrounding support cells
MSC-derived exosomes may also contribute to these effects by carrying neurotrophic factors and other signaling molecules involved in repair. Neurotrophic factors such as nerve growth factors, brain-derived neurotrophic factors, and glial cell line-derived neurotrophic factors are especially important in neurological research because they help support nerve cell survival, growth, and communication.
Another interesting mechanism discussed in the review is mitochondrial transfer. Researchers have found that MSCs may help support stressed or injured cells by transferring mitochondria, which are responsible for producing energy inside cells. This process may help restore cellular function and improve survival in damaged tissues.
The Role of Umbilical Cord and Wharton’s Jelly MSCs
The review also discussed several MSC sources, including bone marrow, placental tissue, umbilical cord tissue, and Wharton’s jelly. Umbilical cord and Wharton’s jelly-derived MSCs are especially relevant in regenerative medicine because they are considered accessible, biologically active, and associated with strong immunomodulatory properties.
Several more recent clinical studies included in the review explored umbilical cord-derived MSCs or Wharton’s jelly MSCs for spinal cord injury. These studies are part of the growing interest in donor-derived MSC sources that can be prepared, characterized, and used in a more standardized way.
The authors noted that future research is still needed to determine which MSC source, dosing strategy, and delivery route may provide the greatest benefit for different types of spinal cord injury. However, the growing number of studies involving umbilical cord and placental sources reflects the continued evolution of MSC-based regenerative medicine.
Advancing MSC Therapy Through Combination Strategies
Another important part of the review focused on future strategies that may improve the effects of MSC therapy. Researchers are exploring ways to enhance MSC-based treatment by combining cells with other regenerative tools.
These strategies may include:
- MSC-derived exosomes
- Tissue-engineering scaffolds
- Biomaterials that support cell survival
- Genetically enhanced MSCs
- Combination therapy with other supportive cells
- Neuromodulation techniques such as electrical stimulation
Scaffolds and biomaterials may help guide tissue repair and provide structural support in the damaged spinal cord environment. Exosomes may allow researchers to deliver many of the signaling benefits associated with MSCs. Genetic modification may also help enhance the release of specific therapeutic factors involved in nerve protection and regeneration.
Together, these innovations point toward a more advanced future for regenerative medicine, where MSC therapy may be personalized or combined with other technologies to better support recovery.
Why This Research Matters
Spinal cord injury can have a major impact on mobility, independence, and quality of life. Because recovery can be limited by inflammation, scarring, and the nervous system’s reduced ability to regenerate, researchers continue to search for approaches that can support repair from multiple angles.
This review highlights the growing body of clinical research involving MSC-based therapy for spinal cord injury. While outcomes varied across studies, the overall findings support continued investigation into MSCs as a promising regenerative medicine approach.
The review also shows that the field is becoming more sophisticated. Researchers are not only asking whether MSCs may help, but also how they should be delivered, which cell sources may be most useful, what dose may be appropriate, and how combination strategies may improve outcomes.
A Promising Area of Neurological Regenerative Medicine
Mesenchymal stem cells continue to be an important focus in spinal cord injury research because of their ability to influence inflammation, release repair-related signals, and support the damaged tissue environment. Clinical studies summarized in this review suggest that MSC-based therapies have demonstrated safety and feasibility, along with encouraging findings related to neurological and functional improvement in some patients.
As research continues, larger and more standardized clinical trials will help clarify the best approaches for using MSCs in spinal cord injury. With continued advances in cell therapy, exosomes, tissue engineering, and neuromodulation, MSC-based regenerative medicine may play an increasingly important role in the future of neurological repair.
Source Shkap M, Namestnikova D, Cherkashova E, Chudakova D, Biktimirov A, Yarygin K, Baklaushev V. Clinical insights into mesenchymal stem cell applications for spinal cord injury. Int J Mol Sci. 2025 Dec 17;26(24):12139. doi: 10.3390/ijms262412139. PMID: 41465577; PMCID: PMC12733355. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12733355/
Related Treatment Pages